Navigation Links
ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
Date:10/21/2008

- Multi-Center Study in Skin Graft Donor Site Patients -

ADDISON, Texas, Oct. 21 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) today announced that it has commenced a clinical study to evaluate patients with graft donor sites treated with Altrazeal(TM) Silver compared with a market leading silver containing carboxymethylcellulose dressing. The study will be conducted at four clinical sites with 40 evaluable patients being enrolled. The first study site has been initiated and the Company plans to initiate additional sites within the next 30-days.

Each patient will have two skin graft donor sites, with Altrazeal(TM) Silver being applied to one site and the competitive dressing being applied to the other site. The primary study objective is to evaluate wound healing. Secondary study objectives include evaluating the incidence of wound infection, number of dressing changes, patient pain and provider and patient satisfaction.

This study is designed to support the marketing of Altrazeal(TM) Silver and provide the necessary clinical data to apply for a CE mark which will enable Altrazeal(TM) Silver to be marketed in Europe and Canada.

Commenting on the clinical study, Renaat Van Den Hooff, Executive Vice President of Operations stated, "Silver containing dressings are used extensively in the skin graft donor site indication to protect against infection. Preliminary data that has been generated in skin graft donor sites with Altrazeal(TM) is very positive, indicating that both patient comfort and pain are improved with Altrazeal(TM). With the use of silver containing dressings increasing in both chronic wounds and burns, this product line extension is an important component of our wound care franchise."

Silver has broad-spectrum antimicrobial properties which is ideal for use in preventing and treating infected wounds and wounds at risk of infection. Reducing bacteria burden in the wounds has been shown to improve
'/>"/>

SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
2. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
5. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
6. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
7. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
8. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
9. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
10. In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices
11. Burcon announces GRAS status for Puratein(R) & Supertein(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...., Dec. 4 AstraZeneca (N...Drug Administration (FDA) has approved once-daily ...elease Tablets as adjunctive (add-on) treatment to...isorder (MDD). SEROQUEL XR is the only medication ...or depressive disorder as adjunctive therapy and a...
(Date:12/3/2009)...Dec. 3 A genetic variati...g a potentially life-threatening blood disorder if...emicals is one of several medical discoveries scie...ics (NYSE: DGX ) will present during the 51st Am...and Exposition, December 5-8, 2009, in New Orleans...
(Date:12/3/2009)...el., Dec. 3 ParagonRx, a Delaware-...management and optimal medication use, will host a...raft guidance on REMS - Risk Evaluation Mitigation... lifecycle management. Dr. Gary Slatko, chief med...d risk management programs, will lead the one-hour...
Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3No Increase in Brain Tumors Seen From Cell Phones 62563 1No Increase in Brain Tumors Seen From Cell Phones 62563 2No Increase in Brain Tumors Seen From Cell Phones 62563 3RN SuperUnion Founding Convention Opens Monday 62559 1RN SuperUnion Founding Convention Opens Monday 62559 2Wayne State Researchers Report a Possible Proofreading Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 62555 1Wayne State Researchers Report a Possible Proofreading Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 62555 2Wayne State Researchers Report a Possible Proofreading Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 62555 3
...the human vaccine business unit of Schering-Plough...it has reached an important milestone with the ini... program for SCH 900795, a new intranasal Live Att...al use. , , The candidate vaccine is composed of ... by the World Health Organization (WHO) for season...
...esented at USCAP Meeting , , SOUTH SAN FRANCISCO,...sdaq: RIGL ) today announced the enrollment of t...al trial of R788 (fostamatinib disodium) in patien...ymphoma (PTCL). The clinical trial,s primary obje... bio-available Syk kinase inhibitor, in patients s...
Other Medicine Technology:Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development 2Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development 3Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 2Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 3
(Date:12/4/2009)..., , PEMBROKE, Bermuda, Dec. 4 /PRNew... Holdings, Ltd (NYSE: AWH ) today announced that...ficer, and Jack Sennott, Executive Vice,President ...enting at the 2009,Goldman Sachs U.S. Financial Se...Conference Center in New York City on Tuesday, Dec...
(Date:12/4/2009)..., , ANAHEIM, Calif., Dec. 4 /PRNewswire/...scent Healthcare, was selected as a finalist for t...forming Crescent,s business with the power of clou...ased on their innovative usage of Salesforce CRM o... customer success to their sales, marketing, partn...
(Date:12/4/2009)..., Working with mice, scientists at Johns Hopkins...ave shown that a protein made by a gene called "Tw...ately distinguish stem cells that drive aggressive...r cells. , Building on recent work suggesting th...in breast tumors that drives breast cancer, scient...
(Date:12/4/2009)...Outcomes same whether procedure done immediately o... Dec. 4 (HealthDay News) -- Timing of surgical rep...juries may not affect patient outcome, a new study...esult from traumatic knee dislocations that can oc...s. The optimal time to perform surgery to repair t...
(Date:12/4/2009)...Research and surveillance urged for at-risk patien...ews) -- Some childhood cancers, particularly Ewing... the risk of late recurrence, U.S. researchers hav... 12,795 five-year survivors of the most common ped...Cancer Survivor Study. , The researchers found ...
Breaking Medicine News(10 mins):Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2
... screenwriters have a lower life expectancy than n...ainly improve your health and longevity - but it d..., Texas, reveal the health risks of winning an Aca...4 years than mere nominees. This is despite having...
...rong connection between celiac disease and diabete...eliac disease in people with type 1 diabetes is ab.... Doctors have uncovered a new finding for diabeti...tion to gluten. Both CD and diabetes are common ch...
...ciation for Continence, a new study shows early in...evalence of incontinence. Incontinence is loss of ...any conditions can cause incontinence,// including... ...
...t they may one day be able to reverse some cases o...indings from an animal study that show infertile m...on to produce offspring.// According to resea...f those are a result of problems with sperm produc...
...th Care System, obese adults who undergo 'stomach ...covered 'hunger hormone' than either normal-weight... Dr. David E. Cumming from the Puget Sound Health...oblems such as type 2 diabetes and other chronic d...
... play a role in reducing the number of childhood d...who tested three different methods of zinc adminis...zinc reduced the risk of prolonged diarrhea// defi...er or the child's caregiver. More than 3 mill...
Other Medicine News:Health News:Decrease of 'Hunger Hormone' after Obesity Surgery 2
...YDON is a long-pulsed Nd:YAG laser system with a w...deep-lying, superficial as well as red and blue ve...pilation in patients with darker skin types (1 to ...vement of skin texture. The handpieces special des...
...he UroVysion Bladder Cancer Kit (UroVysion Kit) is...7, 17, and loss of the 9p21 locus via fluorescence...rom persons with hematuria suspected of having bla...tended for use, in conjunction with and not in lie...
The BTA TRAK® Assay
ARION Long-Pulsed Alexandrite Laser System
Medicine Products: